With 488.85 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.96 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.551 whereas the lowest price it dropped to was $0.57. The 52-week range on BIAF shows that it touched its highest point at $3.16 and its lowest point at $0.24 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 3.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIAF was up-trending over the past week, with a rise of 278.47%, but this was up by 165.85% over a month. Three-month performance surged to 22.50% while six-month performance fell -47.09%. The stock lost -46.04% in the past year, while it has gained 19.78% so far this year. A look at the trailing 12-month EPS for BIAF yields -0.75 with Next year EPS estimates of -0.21. For the next quarter, that number is -0.16. This implies an EPS growth rate of 40.01% for this year and 52.52% for next year.
Float and Shares Shorts:
At present, 15.58 million BIAF shares are outstanding with a float of 9.42 million shares on hand for trading. On 2025-03-14, short shares totaled 0.24 million, which was 133.00001 higher than short shares on 1739491200. In addition to Mr. Steven Girgenti as the firm’s Founder & Executive Chairman of the Board, Ms. Maria Zannes J.D. serves as its Founder, President, CEO & Director.
Institutional Ownership:
Through their ownership of 0.03437 of BIAF’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BIAF reported revenue of $2350386.0 and operating income of -$1973864.0. The EBITDA in the recently reported quarter was -$1825352.0 and diluted EPS was -$0.16.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.69 being high and -$0.69 being low. For BIAF, this leads to a yearly average estimate of -$0.69.
